Résumé
Purpose: To identify characteristics of patients with early open-angle glaucoma exhibiting greater macular perfusion density (PD) loss compared with macular ganglion cell layer (GCL) thickness loss. Design: Cross-sectional study. Methods: Optical coherence tomography (OCT) imaging of the optic nerve head and macula was conducted in patients and healthy control subjects. Minimum rim width, retinal nerve fiber layer and GCL thickness, and PD from OCT angiography were derived. Only high-quality images were included. For direct comparison, raw PD and GCL thickness values in patients were converted to relative age-corrected loss values based on data from controls. Demographic and ocular variables related to greater PD loss compared with GCL thickness loss were identified with multivariate logistic regression. Results: Data from 89 patients (median mean deviation with the 24-2 and 10-2 tests, Humphrey Field Analyzer: −1.96 dB and −1.49 dB, respectively) and 54 controls were analyzed. Sixty-three (71%) patients had relatively more GCL thickness loss, whereas 26 (29%) had relatively more PD loss. More PD loss was associated with lower OCT and OCT-angiography signal strength (odds ratio [95% confidence interval], 0.64 [0.40, 0.96] and 0.60 [0.38, 0.86], per dB, respectively), thicker retinal nerve fiber layer thickness (1.08 [1.01, 1.16] per μm), and female sex (6.57 [1.25, 48.79]). Conclusion: Less than one-third of patients with early glaucoma had more loss of perfusion compared with conventional structural loss in the macula. Even within a range of high-quality images, lower signal strength may be at least partially responsible for apparent perfusion loss.
Langue d'origine | English |
---|---|
Pages (de-à) | 39-47 |
Nombre de pages | 9 |
Journal | American Journal of Ophthalmology |
Volume | 221 |
DOI | |
Statut de publication | Published - janv. 2021 |
Note bibliographique
Funding Information:All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. Funding/Support: This study was supported by the Canadian Institutes of Health Research, Canada (grant # PJT159564; B.C.C.), Alcon Research Institute, United States (B.C.C.), Dalhousie Medical Research Foundation, Canada (B.C.C.), and a Mathers Research Fellowship (C.A.S.). Financial Disclosures: J.R.V. is the consultant for EadieTech. L.M.S. is the consultant for Alcon, Allergan, Bausch and Lomb, and Thea Pharmaceuticals. P.E.R. is the consultant for Allergan and Bausch and Lomb, and lecturer for Bausch and Lomb. M.T.N. is the consultant and lecturer for Allergan and Alcon. B.C.C. receives equipment support from CenterVue, Heidelberg Engineering, and Topcon. The other authors indicate no conflicts of interest. All authors attest that they meet the current ICMJE criteria for authorship.
Funding Information:
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. Funding/Support: This study was supported by the Canadian Institutes of Health Research, Canada (grant # PJT159564; B.C.C.), Alcon Research Institute, United States (B.C.C.), Dalhousie Medical Research Foundation, Canada (B.C.C.), and a Mathers Research Fellowship (C.A.S.). Financial Disclosures: J.R.V. is the consultant for EadieTech. L.M.S. is the consultant for Alcon, Allergan, Bausch and Lomb, and Thea Pharmaceuticals. P.E.R. is the consultant for Allergan and Bausch and Lomb, and lecturer for Bausch and Lomb. M.T.N. is the consultant and lecturer for Allergan and Alcon. B.C.C. receives equipment support from CenterVue, Heidelberg Engineering, and Topcon. The other authors indicate no conflicts of interest. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2020 Elsevier Inc.
ASJC Scopus Subject Areas
- Ophthalmology
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't